Robert Rolleri

907 total citations · 1 hit paper
32 papers, 613 citations indexed

About

Robert Rolleri is a scholar working on Surgery, Dermatology and Epidemiology. According to data from OpenAlex, Robert Rolleri has authored 32 papers receiving a total of 613 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Surgery, 13 papers in Dermatology and 7 papers in Epidemiology. Recurrent topics in Robert Rolleri's work include Hidradenitis Suppurativa and Treatments (12 papers), Colorectal and Anal Carcinomas (8 papers) and Microscopic Colitis (7 papers). Robert Rolleri is often cited by papers focused on Hidradenitis Suppurativa and Treatments (12 papers), Colorectal and Anal Carcinomas (8 papers) and Microscopic Colitis (7 papers). Robert Rolleri collaborates with scholars based in United States, United Kingdom and Belgium. Robert Rolleri's co-authors include William P. Forbes, William J. Sandborn, Enoch Bortey, Craig Paterson, Guangyong Zou, Geert D’Haens, Margaret K. Vandervoort, Brian G. Feagan, Barrett G. Levesque and Gregor B. E. Jemec and has published in prestigious journals such as The Lancet, Gastroenterology and The American Journal of Gastroenterology.

In The Last Decade

Robert Rolleri

25 papers receiving 599 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials

2024 71 citations Alexa B. Kimball, Gregor B. E. Jemec et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robert Rolleri United States	8	256	252	248	224	171	32	613
Vincenzo Bruzzese Italy	10	57 0.2×	110 0.4×	117 0.5×	69 0.3×	79 0.5×	34	348
E. Fréling France	6	22 0.1×	160 0.6×	87 0.4×	215 1.0×	68 0.4×	7	327
S. H. Murch United Kingdom	6	27 0.1×	198 0.8×	130 0.5×	203 0.9×	30 0.2×	14	359
Lucia Liotti Italy	16	109 0.4×	69 0.3×	174 0.7×	14 0.1×	55 0.3×	60	667
Isabelle M. Sanchez United States	13	245 1.0×	101 0.4×	59 0.2×	14 0.1×	154 0.9×	27	415
Shany Sherman Israel	12	160 0.6×	146 0.6×	48 0.2×	13 0.1×	110 0.6×	44	406
A H Birnbaum United States	10	18 0.1×	124 0.5×	289 1.2×	86 0.4×	63 0.4×	16	588
Alexandra Gutierrez United States	11	12 0.0×	246 1.0×	168 0.7×	304 1.4×	69 0.4×	26	455
Nasrin Behniafard Iran	11	88 0.3×	38 0.2×	25 0.1×	50 0.2×	149 0.9×	41	334
Alberto J. S. Duarte Brazil	11	22 0.1×	145 0.6×	60 0.2×	91 0.4×	143 0.8×	20	463

Countries citing papers authored by Robert Rolleri

Since Specialization

Citations

This map shows the geographic impact of Robert Rolleri's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Rolleri with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Rolleri more than expected).

Fields of papers citing papers by Robert Rolleri

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Rolleri. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Rolleri. The network helps show where Robert Rolleri may publish in the future.

Co-authorship network of co-authors of Robert Rolleri

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Rolleri. A scholar is included among the top collaborators of Robert Rolleri based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Rolleri. Robert Rolleri is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chovatiya, Raj, Seth Forman, Afsáneh Alavi, et al.. (2025). 61888 Bimekizumab efficacy by disease duration in moderate to severe hidradenitis suppurativa: 2-year phase 3 results from BE HEARD EXT. Journal of the American Academy of Dermatology. 93(3). AB135–AB135.

Kirby, Joslyn S., et al.. (2025). Psychometric validation and interpretation thresholds of the Hidradenitis Suppurativa Quality of Life (HiSQOL©) questionnaire using pooled data from the phase III BE HEARD I & II trials of bimekizumab in hidradenitis suppurativa. British Journal of Dermatology. 193(1). 93–104.

Ingram, John R, et al.. (2025). Hidradenitis Suppurativa Symptom Daily Diary (HSSDD) and Questionnaire (HSSQ): Psychometric Validation and Interpretation Threshold Derivation Using Phase 3 Study Data. Dermatology and Therapy. 15(5). 1093–1111.

Sayed, Christopher J., Amit Garg, Haley B. Naik, et al.. (2025). Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extension. Journal of the American Academy of Dermatology. 94(3). 867–878.

Shi, Vivian Y., John R Ingram, Hadar Lev‐Tov, et al.. (2025). Bimekizumab Impact on Patient-Reported Outcomes in Patients with Moderate to Severe Hidradenitis Suppurativa: Pooled 48-Week Results from BE HEARD I&II. Dermatology and Therapy. 15(9). 2553–2570.

Orenstein, Lauren A.V., Vivian Y. Shi, Hadar Lev‐Tov, et al.. (2024). Bimekizumab Impact on Pain in Moderate to Severe Hidradenitis Suppurativa: Week 16 Results from BE HEARD I & II. SKIN The Journal of Cutaneous Medicine. 8(1). s350–s350. 2 indexed citations

Zouboulis, Christos C., Amit Garg, Christopher J. Sayed, et al.. (2024). Bimekizumab Efficacy and Safety Through 2 years in Patients with Hidradenitis Suppurativa: Results from the Phase 3 BE HEARD I&II trials and Open-Label Extension BE HEARD EXT. SKIN The Journal of Cutaneous Medicine. 8(6). s473–s473. 1 indexed citations

Kimball, Alexa B., Gregor B. E. Jemec, Christopher J. Sayed, et al.. (2024). Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials. The Lancet. 403(10443). 2504–2519. 71 indexed citations breakdown →

Ingram, John R, et al.. (2023). PCR149 Determination of Ranges of HiSQOL Scores Defining Clinically Meaningful Within-Patient Improvement Thresholds and Severity Levels. Value in Health. 26(12). S477–S477. 2 indexed citations

10.

Garg, Amit, Robert Rolleri, Luke Peterson, et al.. (2023). Validation of the Hidradenitis Suppurativa Investigator Global Assessment. JAMA Dermatology. 159(6). 606–606. 6 indexed citations

11.

Ingram, John R, et al.. (2023). Electronic Patient-Reported Outcomes in Hidradenitis Suppurativa: Content Validity and Usability of the Electronic Hidradenitis Suppurativa Symptom Daily Diary, Hidradenitis Suppurativa Symptom Questionnaire, and Hidradenitis Suppurativa Quality of Life Questionnaire. Dermatology. 240(1). 65–76. 4 indexed citations

12.

Bosworth, Brian P., Glenn L. Gordon, William J. Sandborn, et al.. (2021). Budesonide Foam Induces Remission in Patients With Mild to Moderate Ulcerative Proctitis and Ulcerative Proctosigmoiditis. UNC Libraries. 1 indexed citations

13.

Glatt, Sophie, Gregor B. E. Jemec, Seth Forman, et al.. (2021). Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa. JAMA Dermatology. 157(11). 1279–1279. 112 indexed citations

14.

Lebwohl, Mark, Andrew Blauvelt, C. Paul, et al.. (2018). Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT). Journal of the American Academy of Dermatology. 79(2). 266–276.e5. 101 indexed citations

15.

Piguet, Vincent, Andrew Blauvelt, Daniel Burge, et al.. (2017). Certolizumab Pegol for the Treatment of Chronic Plaque Psoriasis: DLQI and WPAI Patient-Reported Outcomes from an Ongoing Phase 3, Multicenter, Randomized, Active- and Placebo-Controlled Study (CIMPACT). SKIN The Journal of Cutaneous Medicine. 1. s3–s3. 1 indexed citations

16.

Sandborn, William J., Brian P. Bosworth, Salam Zakko, et al.. (2013). P-149 Efficacy and Safety of Budesonide Foam for Inducing Remission in Mildly to Moderately Active Ulcerative Proctitis or Ulcerative Proctosigmoiditis. Inflammatory Bowel Diseases. 19. S83–S83.

17.

Sandborn, William J., Brian P. Bosworth, Salam Zakko, et al.. (2013). Budesonide Foam for Inducing Remission in Active Mild-to-moderate Ulcerative Proctitis or Ulcerative Proctosigmoiditis: Results of Two Randomized, Placebo-controlled Trials. The American Journal of Gastroenterology. 108. S542–S542.

18.

Bass, Almasa, Jeffrey G. Stark, Glenn C. Pixton, et al.. (2012). Dose Proportionality and the Effects of Food on Bioavailability of an Immediate-Release Oxycodone Hydrochloride Tablet Designed to Discourage Tampering and Its Relative Bioavailability Compared With a Marketed Oxycodone Tablet Under Fed Conditions: A Single-Dose, Randomized, Open-Label, 5-Way Crossover Study in Healthy Volunteers. Clinical Therapeutics. 34(7). 1601–1612. 7 indexed citations

19.

White, William B., et al.. (2008). Utility of semiautomatic clinic and 24-h ambulatory blood pressure measurements to evaluate combination therapy: the Ramipril–Hydrochlorothiazide Hypertension Trial. Journal of Human Hypertension. 22(8). 559–568. 3 indexed citations

20.

Clifton, G. Dennis, Michael R. Harrison, Daniel P. Wermeling, et al.. (1994). Pharmacokinetics and pharmacodynamics of a new cardiotonic vasodilator agent, 349U85, in normal subjects. Clinical Pharmacology & Therapeutics. 55(1). 55–63. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact